Use of herpes zoster subunit vaccine to revaccinate previous recipients of the live attenuated zoster vaccine

January 11, 2018

Share article

Previous studies have found that the protection against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years. The authors were interested in whether revaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induces comparable immune responses in previous ZVL recipients and ZVL-naive participants (HZ-NonVac). They performed an open-label study where adults ≥65 years who were vaccinated with ZVL ≥5 years previously (HZ-PreVac) were matched to ZVL-naive adults (HZ-NonVac). All participants received two doses of HZ/su 2 months apart. In the 430 participants recruited, the humoral immune response to HZ/su was found to be noninferior in HZ-PreVac compared with HZ-NonVac (adjusted geometric mean concentration ratio 1.04, 95%CI 0.92-1.17). Cellular immunogenicity, reactogenicity and safety appeared to be similar between the two groups. HZ/su was well-tolerated, with no safety concerns raised within 1 month of the second post-dose. Therefore HZ/su induces a strong immune response irrespective of prior vaccination with ZVL and therefore may be an attractive option to revaccinate prior ZVL recipients.

Read more here

Grupping K, Campora L, Douha M, Heineman TC, Klein NP, et al. ISSN: J Infect Dis; 216(11): 1343-1351.


Added: January 11, 2018